Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2012 1
2016 2
2017 3
2018 1
2019 2
2020 2
2021 2
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Makker V, et al. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045221 Clinical Trial.
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. von Minckwitz G, et al. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. N Engl J Med. 2017. PMID: 28581356 Free PMC article. Clinical Trial.
Preclinical and clinical development of palbociclib and future perspectives.
de Dueñas EM, Gavila-Gregori J, Olmos-Antón S, Santaballa-Bertrán A, Lluch-Hernández A, Espinal-Domínguez EJ, Rivero-Silva M, Llombart-Cussac A. de Dueñas EM, et al. Among authors: santaballa bertran a. Clin Transl Oncol. 2018 Sep;20(9):1136-1144. doi: 10.1007/s12094-018-1850-3. Epub 2018 Mar 21. Clin Transl Oncol. 2018. PMID: 29564714 Review.
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.
Albanell J, Pérez-García JM, Gil-Gil M, Curigliano G, Ruíz-Borrego M, Comerma L, Gibert J, Bellet M, Bermejo B, Calvo L, de la Haba J, Espinosa E, Minisini AM, Quiroga V, Santaballa Bertran A, Mina L, Bellosillo B, Rojo F, Menéndez S, Sampayo-Cordero M, Popa C, Malfettone A, Cortés J, Llombart-Cussac A. Albanell J, et al. Among authors: santaballa bertran a. Clin Cancer Res. 2023 Jan 4;29(1):67-80. doi: 10.1158/1078-0432.CCR-22-1281. Clin Cancer Res. 2023. PMID: 36165912 Free PMC article. Clinical Trial.
Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer.
Alvarez-Lopez I, Bezares S, Dalmau Portulas E, García-Martínez E, García-Sáenz JÁ, Gil-Gil M, Martínez de Dueñas E, Ribelles N, Santaballa Bertrán A. Alvarez-Lopez I, et al. Among authors: santaballa bertran a. Clin Transl Oncol. 2020 Aug;22(8):1364-1377. doi: 10.1007/s12094-019-02269-7. Epub 2020 Feb 12. Clin Transl Oncol. 2020. PMID: 32052382 Free PMC article.
New clinical trials regulation in Spain: analysis of royal decree 1090/2015.
Martin Jimenez M, Calvo Ferrandiz A, Aparicio Urtasun J, Garcia-Campelo R, Gonzalez-Flores E, Lazaro Quintela M, Muñoz Mateu M, Rodriguez Sanchez CA, Santaballa Bertran A, Sepulveda Sanchez JM, Vera Garcia R, Virizuela Echaburu JA, Segui Palmer MA. Martin Jimenez M, et al. Among authors: santaballa bertran a. Clin Transl Oncol. 2017 Mar;19(3):291-300. doi: 10.1007/s12094-016-1550-9. Epub 2016 Oct 7. Clin Transl Oncol. 2017. PMID: 27718157 Free PMC article.
Current Status of Cardio-Oncology in Spain: A National Multidisciplinary Survey.
Martín-García A, Mitroi C, García Sanz R, Santaballa Bertrán A, Arenas M, López-Fernández T; Spanish National Cardio-Oncology Working Group. Martín-García A, et al. Among authors: santaballa bertran a. Rev Esp Cardiol (Engl Ed). 2019 Jan;72(1):84-86. doi: 10.1016/j.rec.2017.11.002. Epub 2017 Dec 6. Rev Esp Cardiol (Engl Ed). 2019. PMID: 29203166 English, Spanish. No abstract available.
14 results